drugset / Trial / NCT00791323

Efficacy of Ketorolac 0.4% in Prostaglandin Suppression

NCT00791323

Phase 4 Completed 9 enrolled Allergan
RandomizedParallel-groupDouble-blindBasic science

Summary

A pilot study to evaluate the extent of PGE2 inhibition (mean aqueous values) by Ketorolac 0.04% following peripheral iridotomy

Timeline

Start
2008-11
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ketorolac Other / unclassified 0.4 % Topical

Indications

No indication recorded.